Stocklytics Platform
Asset logo for symbol ALXO
ALX Oncology Holdings
ALXO47
$1.85arrow_drop_down1.07%-$0.02
Penny Stock
Asset logo for symbol ALXO
ALXO47

$1.85

arrow_drop_down1.07%

Performance History

Chart placeholder
Key Stats
Open$1.85
Prev. Close$1.86
EPS-2.97
DividendNon-Dividend
Next Earnings Date-
Dividend Yield %-
Market Cap$97.57M
PE Ratio-
LOWHIGH
Day Range1.76
1.93
52 Week Range1.19
17.82
Ratios
Revenue-
EBITDA Margin %-
EPS-2.97

Score Breakdown

Welcome to Stocklytics

Don't miss out on the opportunity to stay ahead in the ever-changing world of finance.

Analyst Forecast

Period: Next 12 Months

Analyst Ratings

About ALX Oncology Holdings (ALXO)

ALX Oncology Holdings Inc. (ALXO) is a biopharmaceutical company that focuses on the development and commercialization of therapies for the treatment of cancer. The company's lead product candidate is ALX148, a CD47 blocker that is designed to disrupt the "don't eat me" signal emitted by cancer cells. By blocking this signal, ALX148 enhances the ability of the body's immune system to recognize and attack cancer cells. ALX148 is being evaluated in multiple clinical trials for various types of solid tumors and hematological malignancies.
ALX Oncology's mission is to improve the lives of patients with cancer by developing innovative and effective therapies. The company is committed to leveraging its deep understanding of the immune system and cancer biology to develop targeted treatments that can make a meaningful difference in patients' outcomes. ALX Oncology's research and development efforts are focused on identifying and developing novel therapies that can overcome the challenges associated with cancer treatment.
Sector
Healthcare
Industry
Biotechnology
CEO
Dr. Jaume Pons Ph.D.
Headquarters
South San Francisco
Employees
72
Exchange
NASDAQ
add ALX Oncology Holdings to watchlist

Keep an eye on ALX Oncology Holdings

Adding the right stocks to your watchlist can provide valuable insights and opportunities for strategic decision-making.

Frequently Asked Questions

search
help

What is ALX Oncology Holdings's (ALXO) price per share?

The current price per share for ALX Oncology Holdings (ALXO) is $1.85. The stock has seen a price change of -$0.02 recently, indicating a -1.08% change. This reflects the stock's recent market performance and investor sentiment.
help

What is the 52-week high and low for ALX Oncology Holdings (ALXO)?

For ALX Oncology Holdings (ALXO), the 52-week high is $17.82, which is 863.51% from the current price. The 52-week low is $1.2, the current price is 54.81% above the 52-week low. This gives investors an insight into the stock's volatility and price range over the past year.
help

Is ALX Oncology Holdings (ALXO) a growth stock?

ALX Oncology Holdings (ALXO) has shown an average price growth of -1.65% over the past three years. It has received a score of 10 out of 100 based on the Stocklytics formula. The interpretation of this score in terms of classifying ALX Oncology Holdings as a growth stock may vary, considering it is one of many factors investors might evaluate, including market trends, financial performance, and future prospects of the company.
help

What is ALX Oncology Holdings (ALXO) stock price performance year to date (YTD)?

As of the latest data, ALX Oncology Holdings (ALXO) has a year-to-date price change of 10.78%. Over the past month, the stock has experienced a price change of 7.56%. Over the last three months, the change has been 14.2%. Over the past six months, the figure is -70.91%.
help

Is ALX Oncology Holdings (ALXO) a profitable company?

ALX Oncology Holdings (ALXO) has a net income of -$160.8M, which represents the company's total earnings after all expenses have been deducted from revenues. The gross margin of indicates the percentage of revenue that exceeds the cost of goods sold, and the operating margin of 0% reflects the percentage of revenue remaining after covering variable production costs, highlighting the efficiency of the company's core operations. Total revenue stands at , although specific revenue growth data is currently not available. Operating income is noted at -$170.28M. Furthermore, the EBITDA is -$159.01M.
help

What is the market capitalization of ALX Oncology Holdings (ALXO)?

ALX Oncology Holdings (ALXO) has a market capitalization of $97.57M. The average daily trading volume is 1.86, indicating the stock's liquidity and investor engagement.

Take Your Investments to a Whole New Level